|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grégoire V, Lefebvre JL, Licitra L and
Felip E; EHNS-ESMO-ESTRO Guidelines Working Group, : Squamous cell
carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21
Suppl 5:v184–v186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choong N and Vokes E: Expanding role of
the medical oncologist in the management of head and neck cancer.
CA Cancer J Clin. 58:32–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parfenov M, Pedamallu CS, Gehlenborg N,
Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova
EV, Wilkerson MD, et al: Cancer Genome Atlas Network:
Characterization of HPV and host genome interactions in primary
head and neck cancers. Proc Natl Acad Sci USA. 111:pp. 15544–15549.
2014; View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matta A and Ralhan R: Overview of current
and future biologically based targeted therapies in head and neck
squamous cell carcinoma. Head Neck Oncol. 1:62009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deveraux QL, Stennicke HR, Salvesen GS and
Reed JC: Endogenous inhibitors of caspases. J Clin Immunol.
19:388–398. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ashhab Y, Alian A, Polliack A, Panet A and
Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis
gene with different biological properties and tissue distribution
pattern. FEBS Lett. 495:56–60. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu B, Han M, Wen JK and Wang L:
Livin/ML-IAP as a new target for cancer treatment. Cancer Lett.
250:168–176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Zhang Q, Liu B, Han M and Shan B:
Challenge and promise: Roles for Livin in progression and therapy
of cancer. Mol Cancer Ther. 7:3661–3669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vucic D, Stennicke HR, Pisabarro MT,
Salvesen GS and Dixit VM: ML-IAP, a novel inhibitor of apoptosis
that is preferentially expressed in human melanomas. Curr Biol.
10:1359–1366. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim SA, Yoon TM, Lee DH, Lee JK, Park YL,
Chung IJ, Joo YE and Lim SC: Livin enhances tumorigenesis by
regulating the mitogen-activated protein kinase signaling pathway
in human hypopharyngeal squamous cell carcinoma. Mol Med Rep.
14:515–520. 2016.PubMed/NCBI
|
|
14
|
Lee DH, Yoon TM, Kim SA, Park YL, Lee KH,
Lim SC, Lee JK and Joο YE: Relationship between expression of Livin
and the biological behavior of human oral squamous cell carcinoma.
Oncol Rep. 32:2453–2460. 2014.PubMed/NCBI
|
|
15
|
Yoon TM, Kim SA, Lee DH, Lee JK, Park YL,
Lee KH, Chung IJ, Joo YE and Lim SC: Expression of Livin and the
inhibition of tumor progression by Livin silencing in
laryngohypopharyngeal cancer. In Vivo. 28:751–759. 2014.PubMed/NCBI
|
|
16
|
Pignon JP, Bourhis J, Domenge C and
Designé L: Chemotherapy added to locoregional treatment for head
and neck squamous-cell carcinoma: Three meta-analyses of updated
individual data. MACH-NC Collaborative Group. Meta-Analysis of
Chemotherapy on Head and Neck Cancer. Lancet. 355:949–955. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hitt R, López-Pousa A, Martínez-Trufero J,
Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, et
al: Phase III study comparing cisplatin plus fluorouracil to
paclitaxel, cisplatin, and fluorouracil induction chemotherapy
followed by chemoradiotherapy in locally advanced head and neck
cancer. J Clin Oncol. 23:8636–8645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Posner MR, Hershock DM, Blajman CR,
Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM,
Cullen K, Ervin TJ, et al: TAX 324 Study Group: Cisplatin and
fluorouracil alone or with docetaxel in head and neck cancer. N
Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vermorken JB, Remenar E, van Herpen C,
Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss
JH, et al: EORTC 24971/TAX 323 Study Group: Cisplatin,
fluorouracil, and docetaxel in unresectable head and neck cancer. N
Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yin L, Liu S, Li C, Ding S, Bi D, Niu Z,
Han L, Li W, Gao D, Liu Z, et al: CYLD downregulates Livin and
synergistically improves gemcitabine chemosensitivity and decreases
migratory/invasive potential in bladder cancer: The effect is
autophagy-associated. Tumour Biol. 37:12731–12742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Liu S, Ding K, Ding S, Li C, Lu J,
Gao D, Zhang T and Bi D: Silencing Livin induces apoptotic and
autophagic cell death, increasing chemotherapeutic sensitivity to
cisplatin of renal carcinoma cells. Tumour Biol. 37:15133–15143.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu M, Zhou X, Du Y, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W, et al: miR-20a induces cisplatin
resistance of a human gastric cancer cell line via targeting CYLD.
Mol Med Rep. 14:1742–1750. 2016.PubMed/NCBI
|
|
23
|
Liu F, Chang H, Xu W and Zhai Y: The
effects of Livin shRNA on the response to cisplatin in HepG2 cells.
Oncol Lett. 10:2957–2961. 2015.PubMed/NCBI
|
|
24
|
Zhuang L, Shen LD, Li K, Yang RX, Zhang
QY, Chen Y, Gao CL, Dong C, Bi Q, Tao JN, et al: Inhibition of
livin expression suppresses cell proliferation and enhances
chemosensitivity to cisplatin in human lung adenocarcinoma cells.
Mol Med Rep. 12:547–552. 2015.PubMed/NCBI
|
|
25
|
Zou AM, Wang HF, Zhu WF, Wang FX and Shen
JJ: Effect of RNAi-mediated silencing of Livin gene on biological
properties of colon cancer cell line LoVo. Genet Mol Res.
13:3832–3841. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ding ZY, Liu GH, Olsson B and Sun XF:
Upregulation of the antiapoptotic factor Livin contributes to
cisplatin resistance in colon cancer cells. Tumour Biol.
34:683–693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X, Fan S, Li L, Wang L, Fan G, Zhao Q
and Li Y: RNA interference-mediated knockdown of Livin suppresses
cell proliferation and invasion and enhances the chemosensitivity
to cisplatin in human osteosarcoma cells. Int J Oncol. 43:159–168.
2013.PubMed/NCBI
|
|
28
|
Liu X, Wang A, Gao H, Yuan Z and Jiao Y:
Expression and role of the inhibitor of apoptosis protein livin in
chemotherapy sensitivity of ovarian carcinoma. Int J Oncol.
41:1021–1028. 2012.PubMed/NCBI
|
|
29
|
Wang TS, Ding QQ, Guo RH, Shen H, Sun J,
Lu KH, You SH, Ge HM, Shu YQ and Liu P: Expression of livin in
gastric cancer and induction of apoptosis in SGC-7901 cells by
shRNA-mediated silencing of livin gene. Biomed Pharmacother.
64:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Xu J, Ju S, Ni H, Zhu J and Wang
H: Livin gene plays a role in drug resistance of colon cancer
cells. Clin Biochem. 43:655–660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan D, Liu L, Xu H and Gu D: The effects
on cell growth and chemosensitivity by livin RNAi in non-small cell
lung cancer. Mol Cell Biochem. 320:133–140. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oh BY, Kim KH, Chung SS and Lee RA:
Silencing the livin gene enhances the cytotoxic effects of
anticancer drugs on colon cancer cells. Ann Surg Treat Res.
91:273–277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang SR, Hu GR, Fang LJ, Huang SJ, Li JS,
Zhao MY and Meng MJ: CpG oligodeoxynucleotides enhance
chemosensitivity of 5-fluorouracil in HepG2 human hepatoma cells
via downregulation of the antiapoptotic factors survivin and livin.
Cancer Cell Int. 13:1062013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Huang H, Zhou H, Du T, Zeng L,
Cao Y, Chen J, Lai Y, Li J, Wang G, et al: Activation of nuclear
factor κB pathway and downstream targets survivin and livin by
SHARPIN contributes to the progression and metastasis of prostate
cancer. Cancer. 120:3208–3218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Forastiere AA: Head and neck cancer:
Overview of recent developments and future directions. Semin Oncol.
27 Suppl 8:1–4. 2000.PubMed/NCBI
|
|
36
|
Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN,
Neskey DM and Zhong LP: Induction chemotherapy decreases the rate
of distant metastasis in patients with head and neck squamous cell
carcinoma but does not improve survival or locoregional control: A
meta-analysis. Oral Oncol. 48:1076–1084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Endo T, Abe S, Seidlar HB, Nagaoka S,
Takemura T, Utsuyama M, Kitagawa M and Hirokawa K: Expression of
IAP family proteins in colon cancers from patients with different
age groups. Cancer Immunol Immunother. 53:770–776. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim DK, Alvarado CS, Abramowsky CR, Gu L,
Zhou M, Soe MM, Sullivan K, George B, Schemankewitz E and Findley
HW: Expression of inhibitor-of-apoptosis protein (IAP) livin by
neuroblastoma cells: Correlation with prognostic factors and
outcome. Pediatr Dev Pathol. 8:621–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deveraux QL, Roy N, Stennicke HR, van
Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS and Reed
JC: IAPs block apoptotic events induced by caspase-8 and cytochrome
c by direct inhibition of distinct caspases. EMBO J. 17:2215–2223.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deveraux QL, Takahashi R, Salvesen GS and
Reed JC: X-linked IAP is a direct inhibitor of cell-death
proteases. Nature. 388:300–304. 1997. View
Article : Google Scholar : PubMed/NCBI
|
